Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mastro, L. D.
Right arrow Articles by Melioli, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mastro, L. D.
Right arrow Articles by Melioli, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:505-508, 2001
© 2001 European Society for Medical Oncology

other

Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients

L. Del Mastro1,, M. Venturini1, C. Viscoli2, M. Bergaglio1, A. Signorini1, C. Bighin1, G. Bertelli1, C. Semino3, G. Pietra3, S. Bertoglio2, M. R. Sertoli2, A. Lambiase4, R. Rosso1 and G. Melioli3

1Department of Medical Oncology, National Cancer Research Institute Genoa
2DOBG, Università di Genova Genoa
3Cellular Immunotherapy Unit, National Cancer Research Institute Genoa
4Roche SpA, Milan Italy

Correspondence to: L Del Mastro, MD, Department of Medical Oncology, National Cancer Research Institute L go Rosanna Benzi 10, 16132 Genoa, Italy, E-mail Idelmast{at}hp380.ist.unige.it

Background The majority of high-dose chemotherapy (HDC)-related complications results from bone marrow aplasia, but the graft infusion per se may cause adverse reactions due to the injection of both dimethyl sulfoxide (DMSO) and cell lysis products We evaluated the feasibility of a two-step chemotherapy regimen with peripheral blood progenitor cell (PBPC) support in association with a novel procedure to remove DMSO and products of cell lysis from the cryopreserved cells

Patients and methods Stage III and IV breast cancer patients received induction chemotherapy with three cycles of CEF (cyclophosphamide 600 mg/m2, epirubicin 100 mg/m2, 5-fluorouracil 600 mg/m2) followed by three cycles of HDC consisting of escalating doses of cyclophosphamide (dose range 1200–3000 mg/m2) and carboplatin (dose range 600–1000 mg/m2), supported by DMSO-free PBPC reinfusion. DMSO was removed by a washing/enzymatic digestion procedure

Results Twenty patients received induction chemotherapy and eighteen completed the entire chemotherapy program, a total of fifty-four cycles of HDC were administered Dose limiting toxicity of HDC was long-lasting grade 4 neutropenia associated with documented infection The maximum tolerated dose (MTD) was cyclophosphamide 3000 mg/ m2 and carboplatin 600 mg/m2 No side effects related to PBPC reinfusion were observed

Conclusions The proposed two-step chemotherapy regimen, associated with a novel washing/enzymatic digestion procedure, is feasible in advanced breast cancer patients in the absence of complications related to the specific toxicity of PBPC reinfusion

adverse effects, cryopreservation, colony-stimulating factors, dimethyl sulfoxide


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.